Medicare changes in 2026: What seniors need to know

Significant updates are coming to Medicare in 2026, and knowing what’s changing can help save money and avoid surprises.

Most of these shifts stem from the Inflation Reduction Act (IRA) and ongoing Medicare benefit redesigns that aim to make prescription premiums more predictable.

At-a-glance: 2026 Medicare changes
Here are five changes seniors can expect to shape costs and coverage in 2026: negotiated prices for some high-spend Part D, a $2,000 annual cap on Part D out-of-pocket costs (with an option to spread payments monthly), continued limits on premium growth, ongoing $35 insulin caps and $0 vaccines, and inflation rebates that help curb drug price hikes.

Bottom line: 2026 is expected to bring more predictable pharmacy bills and steadier premiums, though exact savings will depend on medications and plan choices. Review , compare plans, and use cost-saving programs to get the most value.

The five Medicare changes to expect in 2026

1) First negotiated drug prices take effect for select Part D
Starting in 2026, Medicare will apply its first negotiated “Maximum Fair Prices” for a set of high-spend Part D. These lower prices are intended to reduce what plans and beneficiaries pay at the pharmacy counter. Not every drug is included — only a limited list qualifies in 2026 — but if one of the medications is on it, lower costs at the point of sale could result. For program details and timelines, see the official CMS materials on the Medicare Drug Price Negotiation Program.

What it means: Potentially lower out-of-pocket costs if a negotiated drug is used, though savings vary by plan and pharmacy. Not all formulations or strengths may be included, and plans may adjust formularies in response.

Do this: Make a list of medications, including dose and frequency. During open enrollment, check plan 2026 formularies and estimated costs.

Ask a pharmacist or clinician: whether a negotiated alternative is appropriate if a current drug isn’t on the list.

2) Part D’s $2,000 annual cap remains — and costs can be spread monthly
Beginning in 2025, Part D introduced a $2,000 annual cap on out-of-pocket prescription drug costs. That cap continues in 2026. Also continuing: the Prescription Payment Plan (often called “smoothing”), which lets enrollees opt in to spread out-of-pocket Part D costs in equal monthly amounts across the year instead of paying large sums all at once.

What it means: If drug costs are high, no more than $2,000 will be paid out of pocket in 2026 for Part D. Smoothing can help cash flow—especially early in the year—by converting big refill bills into predictable monthly payments.

Do this: Estimate 2026 drug spending. If high costs are expected, contact the plan to learn how to enroll in the monthly payment option and how midyear plan changes affect the arrangement.

Watch for: auto-debit rules, missed payment policies, and how refunds/credits work if change or the cap is reached.

3) Part D premium growth is limited by law
Through the end of the decade, federal law limits annual increases in the base beneficiary premium for Part D. While this does not freeze the exact premium for a specific plan, it is designed to keep average premiums steadier than they might otherwise be.

What it means: Expect fewer sharp swings in the underlying premium benchmark. However, individual plan premiums can still rise or fall depending on benefits and plan design, so comparing options every year remains important.

Do this: Avoid automatic renewals without review. Use the Medicare Plan Finder to compare 2026 premiums, copays, and drug coverage during open enrollment (Oct 15–Dec 7). Review the plan’s Annual Notice of Change (ANOC) to see premium and benefit updates.

4) $35 insulin copays and $0 vaccines continue
The $35 monthly cap for covered insulin (under Part D, and for insulin furnished through pumps under Part B) remains in effect, and ACIP-recommended vaccines covered by Part D (such as shingles and Tdap) continue at $0 cost sharing. These provisions reduce out-of-pocket costs for many beneficiaries.

What it means: Monthly insulin costs should not exceed $35 for each covered insulin product. Recommended vaccines covered by Part D should have no copay or deductible.

Do this: Confirm that the specific brand and formulation of insulin are on the plan formulary and that the pharmacy is in network. Ask a pharmacist about scheduling missed vaccines; these should be covered at $0 when billed to Part D.

5) Inflation rebates help curb price hikes (and may lower some Part B coinsurance)
Drug manufacturers owe rebates to Medicare when prices for many Part B and Part D rise faster than inflation. For certain Part B, these rebates can translate into lower beneficiary coinsurance for affected quarters. The program continues in 2026.

What it means: Reduced coinsurance on some physician-administered (Part B) may appear during specific quarters, depending on price trends. Part D plans benefit indirectly as rebate protections reduce pressure from rapid price increases.

Do this: For those receiving Part B （for example, clinic infusions), ask the provider’s billing staff whether any inflation-adjusted coinsurance applies in 2026. Treat rebates as a protective backstop rather than a guaranteed source of specific savings.

What seniors should do to prepare for 2026

Make a personalized medication and care inventory. List every drug with dose, frequency, and preferred pharmacies; include any physician-administered Part B. This ensures accurate comparisons and helps clinicians suggest lower-cost alternatives if appropriate.

Compare plans during open enrollment. Use the Medicare Plan Finder to check premiums, deductibles, copays, and pharmacy networks for 2026. Pay close attention to whether are on formulary and to utilization rules (prior authorization, step therapy).

Consider the monthly “smoothing” option. If large refills strain a budget, ask the 2026 Part D plan how to opt in to the Prescription Payment Plan and how it interacts with the $2,000 cap.

Check Extra Help (LIS) eligibility. Many more beneficiaries may qualify for substantial help with Part D premiums and cost sharing. Apply through Social Security’s Extra Help (Low-Income Subsidy) to learn about potential savings.

Review Annual Notice of Change documents. Look for premium or formulary changes, pharmacy network shifts, and any updates tied to the 2026 redesign.

Talk to clinicians. Ask whether lower-cost therapeutic alternatives are appropriate, especially if a current drug is not among negotiated products.

Key dates and reminders

Oct 1: Plans begin sending Annual Notice of Change (ANOC).

Oct 15–Dec 7: Medicare Open Enrollment for 2026 coverage.

Jan 1, 2026: New plan year starts; negotiated prices for selected and all 2026 program changes take effect.

Jan 1–Mar 31, 2026: Medicare Advantage Open Enrollment Period (switch MA plans or return to Original Medicare with/without Part D).

Frequently asked questions

Will a plan automatically enroll an enrollee in the monthly payment (smoothing) program?
No. This is generally an opt-in feature. Contact the Part D plan to enroll and ask about billing, missed payment policies, and how therapy changes affect the monthly amount.

Could premiums still rise even with the growth limits?
Yes. The law limits growth in the base premium benchmark, but individual plan premiums can still vary. That is why comparing plans each year is important.

How to know if a drug is one of the negotiated products?
Watch for CMS announcements and check the plan’s 2026 formulary and cost estimator. If a drug isn’t included, ask a clinician whether a negotiated alternative could be suitable.

Sources

• https://www.cms.gov/medicare/medicare-part-d-drug-negotiation-program
• https://www.kff.org/medicare/issue-brief/explaining-the-prescription-drug-provisions-in-the-inflation-reduction-act/
• https://www.cms.gov/about-cms/organization/cms-initiatives/part-d-prescription-payment-plan
• https://www.medicare.gov/plan-compare
• https://www.medicare.gov/coverage/insulin
• https://www.ssa.gov/medicare/part-d-extra-help
• https://www.cms.gov/newsroom/fact-sheets/medicare-part-b-and-part-d-inflation-rebate-programs-fact-sheet